Lung Cancer

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

Upfront Next-Generation Sequencing Is Faster, More Cost Effective in Metastatic NSCLC

Upfront Next-Generation Sequencing Is Faster, More Cost Effective in Metastatic NSCLC

By

The researchers argue that upfront next-generation sequencing should be the new standard of care.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Role of <i>BRAF</i> Mutations in Non-Small Cell Lung Cancer Still Emerging, Evolving

Role of BRAF Mutations in Non-Small Cell Lung Cancer Still Emerging, Evolving

By

"BRAF-mutated NSCLC represents an emerging targetable entity among the scenario of oncogene-driven NSCLC."

Bifunctional Immunotherapy M7824 For Advanced NSCLC, HPV-Associated Cancers

Bifunctional Immunotherapy M7824 For Advanced NSCLC, HPV-Associated Cancers

James L. Gulley, MD, PhD, FACP, discusses his findings at ASCO 2018 meeting.

Gefitinib Plus Platinum-Doublet Chemotherapy May Improve Overall Survival in <i>EGFR</i>-Positive NSCLC

Gefitinib Plus Platinum-Doublet Chemotherapy May Improve Overall Survival in EGFR-Positive NSCLC

By

EGFR tyrosine kinase inhibitor monotherapy has improved progression-free survival (PFS) but not overall survival (OS) compared with chemotherapy in non-small cell lung cancer.

Bevacizumab Plus Erlotinib May Be a New Standard of Care in Non-Small Cell Lung Cancer

Bevacizumab Plus Erlotinib May Be a New Standard of Care in Non-Small Cell Lung Cancer

By

Recent studies have explored the potential of combination therapy with EGFR-TKIs and VEGF-inhibitors for patients with EGFR-positive non-small cell lung cancer.

Cemiplimab for Cutaneous Squamous Cell Carcinoma

Cemiplimab for Cutaneous Squamous Cell Carcinoma

Danny Rischin, MBBS, FRACP, MD, speaks at the American Society of Clinical Oncology (ASCO) 2018 meeting.

Phase II Data of Tepotinib for Non-Small Cell Lung Cancer

Phase II Data of Tepotinib for Non-Small Cell Lung Cancer

Enriqueta Felip, MD, PhD, discusses her findings at the ASCO 2018 meeting in Chicago.

Web-Based Monitoring Resulted in Longer Overall Survival for Patients in Lung Cancer

Web-Based Monitoring Resulted in Longer Overall Survival for Patients in Lung Cancer

By

Previous findings showed a 7 month median overall survival benefit (P = .002) for patients with lung cancer given web-mediated follow-up.

Lung Cancer Screening Rates Inadequate in United States Despite USPSTF Recommendations

Lung Cancer Screening Rates Inadequate in United States Despite USPSTF Recommendations

By

Current literature reflects estimates, but not actual rates, of low-dose computed tomography adherence across the United States.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

By

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Prophylactic Cranial Irradiation Reduces the Incidence of Brain Metastases in NSCLC

Prophylactic Cranial Irradiation Reduces the Incidence of Brain Metastases in NSCLC

By

Some figures show that incidence of brain metastasis is approximately 30% 2 years after being diagnosed with non-small cell lung cancer.

Pembrolizumab and Chemotherapy Combination Significantly Improves PFS in NSCLC

Pembrolizumab and Chemotherapy Combination Significantly Improves PFS in NSCLC

By

The phase 3 study found the combination effective, regardless of tumor proportion score.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

By

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Immunotherapy for Lung Cancer: Are Combination Regimens a Path Forward?

Immunotherapy for Lung Cancer: Are Combination Regimens a Path Forward?

By

PD-1/PD-L1 ICI can offer remarkable benefits as first- and second-line treatments for NSCLC, but 80% of patients do not respond to immunotherapy, and many of those who do respond eventually see their cancers acquire drug resistance.

Timely Reporting of Palliative Care Needs Leads to More Appropriate End-of-Life Care in NSCLC

Timely Reporting of Palliative Care Needs Leads to More Appropriate End-of-Life Care in NSCLC

By

Researchers accessed the French National Hospital registry and obtained the records of 64,950 patients who died of metastatic NSCLC between 2010 and 2013.

Asthma Inhalation Therapies

Asthma inhalation therapies including exercise induced bronchospasm (EIB) and asthma maintenance dosing.

Osimertinib Improves Quality-of-Life and Global Health Status in Non-Small Cell Lung Cancer

Osimertinib Improves Quality-of-Life and Global Health Status in Non-Small Cell Lung Cancer

By

Non-small cell lung cancer largely remains incurable and is associated with high symptom burden and reduced quality of life.

The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

By

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

Phase 1/2 Trial of CAR-T Cell Immunotherapy in Metastatic, Mesothelin-Expressing Cancer

Phase 1/2 Trial of CAR-T Cell Immunotherapy in Metastatic, Mesothelin-Expressing Cancer

By

Researchers are evaluating whether CAR-T cell immunotherapy that targets mesothelin is safe and effective among patients with mesothelin-expressing tumors.

Mesothelioma Treatment Regimens

Access treatment options for mesothelioma in this detailed drug regimen, which includes agents such as pemetrexed + cisplatin and more.

HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

By

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

CTCs May Not Have Genetic Changes Found in Primary Lung Tumors

CTCs May Not Have Genetic Changes Found in Primary Lung Tumors

By

At surgery, blood samples were taken from 163 patients; whole genome sequencing and whole exome signaling were performed on detected CTCs.

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

By

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

By

Phase 1 trials should be considered therapeutic options for some patients.

Crizotinib Leads to Durable Benefit in ROS1-Positive Non-Small Cell Lung Cancer

Crizotinib Leads to Durable Benefit in ROS1-Positive Non-Small Cell Lung Cancer

By

Previous studies have demonstrated that crizotinib — a tyrosine kinase inhibitor (TKI) of ALK, MET, and ROS1 kinases — has markedly increased antitumor activity among patients with ROS1-positive NSCLC.

Immunotherapy and the Risk of Myocarditis

Immunotherapy and the Risk of Myocarditis

By

The risk should not discourage patients with cancer from taking these potentially life-extending therapies.

Long-Term Gefitinib Can Be Effective in Patients With NSCLC

Long-Term Gefitinib Can Be Effective in Patients With NSCLC

By

Few long-term data of the drug's safety and efficacy in patients with NSCLC were previously available.

Lung Cancer: Predicting Response Checkpoint Inhibition

Lung Cancer: Predicting Response Checkpoint Inhibition

By

Assessing tumor mutational burden may help to determine which patients will respond.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs